KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Change in Accured Expenses (2016 - 2026)

Gilead Sciences filings provide 17 years of Change in Accured Expenses readings, the most recent being -$395.0 million for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 229.51% to -$395.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.0 million, a 94.44% decrease, with the full-year FY2025 number at $6.0 million, down 94.44% from a year prior.
  • Change in Accured Expenses hit -$395.0 million in Q4 2025 for Gilead Sciences, down from $811.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.5 billion in Q4 2021 to a low of -$1.7 billion in Q1 2022.
  • Median Change in Accured Expenses over the past 5 years was $37.5 million (2021), compared with a mean of $24.3 million.
  • Biggest five-year swings in Change in Accured Expenses: soared 1348.0% in 2022 and later crashed 229.51% in 2025.
  • Gilead Sciences' Change in Accured Expenses stood at $1.5 billion in 2021, then tumbled by 76.88% to $356.0 million in 2022, then dropped by 10.96% to $317.0 million in 2023, then decreased by 3.79% to $305.0 million in 2024, then crashed by 229.51% to -$395.0 million in 2025.
  • The last three reported values for Change in Accured Expenses were -$395.0 million (Q4 2025), $811.0 million (Q3 2025), and -$166.0 million (Q2 2025) per Business Quant data.